Major depressive disorder (MDD)
Conditions
Interventions
None listed
Sponsors
Takeda Pharmaceutical Company Limited.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The study subjects will be selected from those who can be identified in the claims database and have step count data. The data period in the DeSC database: from April 1, 2015 to August 31, 2021. Eligibility criteria for each analysis are listed in the next section. < Analysis 1 > - To have a record of MDD diagnosis (identified by ICD-10 code of F32-F33). - To have step count data throughout the analysis period. < Analysis 2 > - Insured person (this means that dependents of insured person will not be included in the analysis). - To have WPAI data at least two time points. - To have step count data during all analysis periods which correspond to each subject's WPAI data points. < Analyses 3, 4 > - Insured person. - To have WFun data. - To have step count data during the analysis period.
Exclusion criteria
Exclusion criteria: < Analysis 1 > - To have any record of the following diseases or events during the analysis period: Cancer (ICD-10 code of C00-C97), bipolar disorder (F31), dialysis (identified by searching medical procedures which include a word ""Dialysis""). < Analysis 2 > - To have any record of the following diseases or events during the analysis period: Cancer (ICD-10 code of C00-C97), fracture (S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02), bipolar disorder (F31), dialysis (identified by searching medical procedures which include a word ""Dialysis""), hospitalization. < Analyses 3, 4 > - To have any record of the following diseases or events during the analysis period: Cancer (ICD-10 code of C00-C97), fracture (S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02), bipolar disorder (F31), dialysis (identified by searching medical procedures which include a word ""Dialysis""), hospitalization. - Those who do not carry their smartphone regularly (can be identified by questionnaire)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MDD diagnosis (a surrogate indicator of MDD development, defined by using ICD-10 code) and the number of step. | — |
Secondary
| Measure | Time frame |
|---|---|
| [Web-based questionnaire] Work productivity impairment measured by Work Productivity and Activity Impairment Questionnaire (WPAI) and Work Functioning impairment scale (WFun) Severity of depressive symptom measured by Patient Health Questionnaire-9 (PHQ-9) Level of anhedonia measured by Snaith-Hamilton Pleasure Scale (SHAPS) | — |
Countries
Japan
Contacts
Public ContactFumie Tokuda
Takeda Pharmaceutical Company Limited. Japan Medical Office
Outcome results
None listed